Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI vs Gemcitabine in Resected Pancreatic Cancer (GIP-2)
NCT02355119Phase 3Unknown
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Jan 2015
- Primary completion
- Dec 2017
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of fluorouracil, folinic acid, oxaliplatin, irinotecan in pancreatic cancer (PC), sponsored by Azienda Ospedaliero-Universitaria Pisana. Status: unknown.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02355119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02355119.